Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4852122 | 0.93 | NPSR1 (0.53) | NPSR1POLBPKMCYP3A4CYP2C19 | |
| SCHEMBL14513383 | 0.92 | NPSR1 (0.44) | NPSR1POLBPKMCYP3A4CYP2C19 | |
| SCHEMBL5576909 | 0.88 | PKM (0.43) | PKMTDP1ALDH1A1 | |
| SCHEMBL4856756 | 0.87 | NPSR1 (0.51) | NPSR1POLBPKMKDM4EMAPT | |
| SCHEMBL4859853 | 0.86 | NPSR1 (0.48) | NPSR1POLBPKMCYP3A4CYP2C19 | |
| SCHEMBL5312261 | 0.86 | NPSR1 (0.48) | NPSR1POLBPKMCYP3A4CYP2C19 | |
| Hydrochloric Acid SCHEMBL5311660 | 0.85 | NPSR1 (0.48) | NPSR1POLBPKMCYP3A4CYP2C19 | |
| SCHEMBL5576954 | 0.84 | PTGS1 (0.34) | NPSR1 | |
| SCHEMBL4859966 | 0.81 | NPSR1 (0.46) | NPSR1POLBPKMKDM4EMAPT | |
| SCHEMBL5313256 | 0.80 | PKM (0.39) | PKMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007052831-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-10 | — | — | WO | disclosed |
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099986-A1 | Preventives/remedies for urinary disturbance | REN, GLS, ATP6V1B1 | NPSR1 520/4885POLB 3730/4885PKM 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.